Observational studyMedicine2025
Analysis of risk factors for vascular dementia following thrombolytic therapy in patients with acute ischemic stroke.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study investigated the risk factors associated with the development of vascular dementia (VaD) following intravenous thrombolytic therapy in patients with acute ischemic stroke. A total of 219 patients treated between January 2021 and December 2024 were included, comprising 51 individuals who developed VaD during follow-up and 168 without VaD. Diagnosis of VaD was established using the National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences criteria. Baseline demographic, clinical, laboratory, and imaging data were systematically collected, including vascular risk factors, metabolic indices, inflammatory and immune markers, and lesion characteristics. Univariate analysis demonstrated that smoking, coronary artery disease, hypertension, and alcohol consumption were significantly more prevalent in the VaD group. Laboratory parameters, including elevated blood glucose, Systemic Immune-Inflammation Index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lipoprotein, and D-dimer, were significantly higher among patients with VaD. Imaging findings revealed that severe large-vessel stenosis (≥50%) and infarction involving key cognitive-related regions were strongly associated with VaD. Multivariate logistic regression identified smoking history, coronary artery disease, hyperglycemia, elevated Systemic Immune-Inflammation Index, increased platelet-to-lymphocyte ratio, lipoprotein, D-dimer, large-vessel stenosis, and strategic infarct location as independent predictors. These findings underscore the multifactorial etiology of post-thrombolysis cognitive decline and support the need for comprehensive risk stratification and targeted interventions to mitigate VaD risk in acute ischemic stroke patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.